Martinez S, Sellam V, Marco S, Sanfiorenzo C, Macone F, Marquette C H
Service de Pneumologie, Hôpital Pasteur, CHU de Nice, 30 Avenue de la Voie-Romaine, BP 1069, 06002 Nice cedex 1, France.
Rev Mal Respir. 2011 Jan;28(1):92-6. doi: 10.1016/j.rmr.2010.06.028. Epub 2011 Jan 11.
Modern immunosuppressive therapy may be responsible for toxic, immunologic and infectious pulmonary diseases.
We report the case of a 58-year old woman treated for rheumatoid arthritis who received leflunomide, corticosteroids, methotrexate and adalimumab. She developed disseminated tuberculosis, which presented with neurological symptoms (brainstem) and also pneumocystis pneumonia.
Modern immunosuppressive therapy used to treat inflammatory disorders in connective tissue diseases and in transplantation may induce new respiratory diseases, new patterns of known respiratory diseases or co-infections that are very seldom seen outside the context of HIV. Pulmonologists, rheumatologists, internists and intensivists should be aware of this new spectrum of diseases whose presentation may be atypical.
现代免疫抑制疗法可能导致毒性、免疫性和感染性肺部疾病。
我们报告一例58岁类风湿关节炎女性患者,她接受了来氟米特、皮质类固醇、甲氨蝶呤和阿达木单抗治疗。她发生了播散性结核病,表现为神经症状(脑干),还发生了肺孢子菌肺炎。
用于治疗结缔组织疾病和移植中的炎症性疾病的现代免疫抑制疗法可能诱发新的呼吸系统疾病、已知呼吸系统疾病的新模式或合并感染,这些在艾滋病病毒感染背景之外很少见。肺科医生、风湿科医生、内科医生和重症监护医生应意识到这种疾病谱的新变化,其表现可能不典型。